Teva Announced Saturday, Switching To UZEDY At Four Weeks After The Last Dose Of Once-monthly Paliperidone Palmitate Provided The Most Comparable Pharmacokinetic Profile Based On The Relevant PK Modeling Data For Schizophrenia
Teva Announced Saturday, Switching To UZEDY At Four Weeks After The Last Dose Of Once-monthly Paliperidone Palmitate Provided The Most Comparable Pharmacokinetic Profile Based On The Relevant PK Modeling Data For Schizophrenia
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA),today announced the presentation of seven studies from its long-acting injectable (LAI) schizophrenia research program. Presentations include data informing clinical strategies for switching patients to UZEDY, an extended-release injectable suspension of risperidone for subcutaneous use every one or two months for the treatment of schizophrenia in adults, from a once-monthly intramuscular injection of Invega Sustenna. The results were presented at the Psych Congress Elevate 2024 Annual Meeting taking place from May 30 – June 2 in Las Vegas, Nevada.
梯瓦製藥的美國子公司，Teva Pharmaceuticals宣佈其長效注射型（LAI）精神分裂症研究計劃的七個研究結果，其中包括UZEDY的數據，這是一種每一到兩個月爲成人治療精神分裂症的長效緩釋risperidone注射液，可以替代每月一次的Invega Sustenna肌肉注射。這些結果發佈於5月30日至6月2日在內華達州拉斯維加斯舉辦的2024年心理學會議。
譯文內容由第三人軟體翻譯。